
Join to view full profile
118 Med Surge # 1Irvine, CA 92697
Phone+1 949-824-6211
Fax+1 949-824-4015
Dr. Schiffman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Henry Ford Health/Henry Ford HospitalResidency, Ophthalmology, 1993 - 1996
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1983 - 1986
Universidad Autonoma de Ciudad JuarezClass of 1982
Certifications & Licensure
CA State Medical License 2002 - 2027
MI State Medical License 1984 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
Publications & Presentations
PubMed
- 7 citationsEfficacy of a Preservative-Free Formulation of Fixed-Combination Bimatoprost and Timolol (Ganfort PF) in treatment-naïve Patients vs Previously Treated PatientsM Francesca Cordeiro, Ivan Goldberg, Rhett M. Schiffman, Paula Bernstein, Marina Bejanian
Clinical Ophthalmology. 2015-08-31 - 36 citationsBimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hyperte...Ivan Goldberg, Rafael Gil Pina, Aitor Lanzagorta-Aresti, Rhett M. Schiffman, Charlie Liu
The British Journal of Ophthalmology. 2014-07-01 - 141 citationsDexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular EdemaDavid Callanan, Sunil Gupta, David S. Boyer, Thomas A. Ciulla, Michael A Singer
Ophthalmology. 2013-09-01
Press Mentions
Phase 3 Presbyopia Drop Trial LaunchesApril 6th, 2022
Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of DirectorsAugust 25th, 2021
Visus Therapeutics Expands Ophthalmic Drug Portfolio with Investigational Therapies for Glaucoma and Age-Related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery TechnologyAugust 19th, 2021
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









